Vol. 6 No. 3 (2026)
Reimbursement Reviews

Belantamab Mafodotin (Blenrep), Bortezomib, Dexamethasone

decorative image of the issue cover

Published March 5, 2026

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Belantamab mafodotin (Blenrep) in combination with bortezomib and dexamethasone, 70 mg and 100 mg per single-use vials.
  • Indication: Belantamab mafodotin in combination with bortezomib and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy.